Macrophage endocytic trafficking of antiretroviral nanoparticles

Nanomedicine

Volumn 6, Issue 6, 2011, Pages 975-994

  Kadiu, Irena ^a   Nowacek, Ari ^a   McMillan, JoEllyn ^a   Gendelman, Howard E ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

antiretroviral therapy; drug delivery; endocytic trafficking; HIV; homogenization; monocyte derived macrophages; nanoformulated antiretroviral drugs; Rab11; recycling endosomes

Indexed keywords

ANTIRETROVIRUS AGENT; BREFELDIN A; CLATHRIN; NANOPARTICLE; RAB11 PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG UPTAKE; ENDOCYTOSIS; ENDOSOME; HUMAN; LYSOSOME; MACROPHAGE MIGRATION; MONOCYTE; PRIORITY JOURNAL; PROTEOMICS;

BIOLOGICAL TRANSPORT; ENDOCYTOSIS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNOHISTOCHEMISTRY; LYSOSOMES; MACROPHAGES; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; NANOPARTICLES; NANOTECHNOLOGY; RITONAVIR;

EID: 80052295288     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.27     Document Type: Article

References (75)

1. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH: Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376(9738), 367-387 (2010).
2. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M, Strathdee SA: Time to act: A call for comprehensive responses to HIV in people who use drugs. Lancet 376(9740), 551-563 (2010).
3. Chulamokha L, DeSimone JA, Pomerantz RJ: Antiretroviral therapy in the developing world. J. Neurovirol. 11(Suppl. 1), 76-80 (2005).
4. De Cock KM, De Lay P: HIV/AIDS estimates and the quest for universal access. Lancet 371(9630), 2068-2070 (2008).
5. Wolfe D, Carrieri MP, Shepard D: Treatment and care for injecting drug users with HIV infection: A review of barriers and ways forward. Lancet 376(9738), 355-366 (2010).
6. Broder S: The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85(1), 1-18 (2010).
7. Este JA, Cihlar T: Current status and challenges of antiretroviral research and therapy. Antiviral Res. 85(1), 25-33 (2010).
8. Moreno S, Lopez Aldeguer J, Arribas JR et al.: The future of antiretroviral therapy: Challenges and needs. J. Antimicrob. Chemother. 65(5), 827-835 (2010).
9. Taiwo B, Hicks C, Eron J: Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J. Antimicrob. Chemother. 65(6), 1100-1107 (2010).
10. Anuurad E, Semrad A, Berglund L: Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab. Syndr. Relat. Disord. 7(5), 401-410 (2009).
11. Barbaro G: Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr. Pharm. Des. 13(21), 2208-2213 (2007).
12. Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE: HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol. Dis. 37(3), 542-548 (2010).
13. Kramer AS, Lazzarotto AR, Sprinz E, Manfroi WC: Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV. Arq. Bras. Cardiol. 93(5), 561-568 (2009).
14. Rao KS, Ghorpade A, Labhasetwar V: Targeting anti-HIV drugs to the CNS. Expert Opin. Drug Deliv. 6(8), 771-784 (2009).
15. Varatharajan L, Thomas SA: The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Res. 82(2), A99-A109 (2009).
16. Dou H, Destache CJ, Morehead JR et al.: Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8), 2827-2835 (2006).
17. Dou H, Morehead J, Destache CJ et al.: Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358(1), 148-158 (2007).
18. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE: Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: Implications for neuroAIDS therapeutics. J. Neuroimmune Pharmacol. (2010).
19. Nowacek AS, Miller RL, McMillan J et al.: NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomed. (Lond.) 4(8), 903-917 (2009). nn In vitro analysis demonstrated that nanoART are rapidly taken up and then slowly released by monocyte-derived macrophages. In addition, nanoART were shown to be highly efficacious against HIV replication.
20. Dou H, Grotepas CB, McMillan JM et al.: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183(1), 661-669 (2009). nn Demonstrated that macrophages loaded with nanoART could cross the blood-brain barrier, deliver drug to the brain and inhibit HIV replication in a mouse model of HIV encephalitis.
21. Baert L, van't Klooster G, Dries W et al.: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72(3), 502-508. (2009).
22. Van't Klooster G, Hoeben E, Borghys H et al.: Pharmacokinetics and disposition of rilpivirine (tmc278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 54(5), 2042-2050 (2010). nn In vivo administration of crystalline ART nanoparticles allowed for sustained drug levels for up to 6 months. Observations suggested that nanoparticles were taken up by macrophages upon administration.
23. Nowacek A, Balkundi S, McMillan J et al.: Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control. Release DOI: 10.1016/j.jconrel.2010.11.019 (2010) (Epub ahead of print).
24. Basyuk E, Galli T, Mougel M, Blanchard JM, Sitbon M, Bertrand E: Retroviral genomic RNAs are transported to the plasma membrane by endosomal vesicles. Dev. Cell 5(1), 161-174 (2003).
25. Gendelman HE, Orenstein JM, Martin MA et al.: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167(4), 1428-1441 (1988).
26. Kalter DC, Greenhouse JJ, Orenstein JM, Schnittman SM, Gendelman HE, Meltzer MS: Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease. J. Immunol. 146(10), 3396-3404 (1991).
27. Meltzer MS, Gendelman HE: Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr. Top. Microbiol. Immunol. 181, 239-263 (1992).
28. Meltzer MS, Nakamura M, Hansen BD, Turpin JA, Kalter DC, Gendelman HE: Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res. Hum. Retroviruses 6(8), 967-971 (1990).
29. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, Gendelman HE: Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu. Rev. Immunol. 8, 169-194 (1990).
30. Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH: Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst. Rev. 2, CD006343 (2010).
31. Chu P, Sadullah S: The current role of amphotericin B lipid complex in managing systemic fungal infections. Curr. Med. Res. Opin. 25(12), 3011-3020 (2009).
32. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L: Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 24(2), 51-61 (2010).
33. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A: Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect. Dis. 9, 198 (2009).
34. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA: Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles in mice. J. Antimicrob. Chemother. 65(10), 2183-2187 (2010).
35. Beduneau A, Ma Z, Grotepas CB et al.: Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS ONE 4(2), e4343 (2009).
36. Brynskikh AM, Zhao Y, Mosley RL et al.: Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomed. (Lond.) 5(3), 379-396 (2010).
37. Gorantla S, Dou H, Boska M et al.: Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J. Leukoc. Biol. 80(5), 1165-1174 (2006).
38. Liu Y, Uberti MG, Dou H et al.: Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis. J. Neuroimmunol. 200(1-2), 41-52 (2008).
39. Bareford LM, Swaan PW: Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59(8), 748-758 (2007).
40. Bressani R, Nowacek A, Singh S et al.: Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology (2010) (Epub ahead of print).
41. Marre S, Jensen KF: Synthesis of micro and nanostructures in microfluidic systems. Chem. Soc. Rev. 39(3), 1183-1202 (2010).
42. Muchow M, Maincent P, Muller RH: Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 34(12), 1394-1405 (2008).
43. Takatsuka T, Endo T, Jianguo Y, Yuminoki K, Hashimoto N: Nanosizing of poorly water soluble compounds using rotation/revolution mixer. Chem. Pharm. Bull. (Tokyo) 57(10), 1061-1067 (2009). n Demonstrated how poorly water soluble compounds could be prepared into nanoparticles by wet milling. In addition, they showed that the physical properties of the crystalline particles could be manipulated by altering the manufacturing process.
44. Kumari S, Mg S, Mayor S: Endocytosis unplugged: Multiple ways to enter the cell. Cell Res. 20(3), 256-275 (2010).
45. Hattula K, Furuhjelm J, Tikkanen J, Tanhuanpaa K, Laakkonen P, Peranen J: Characterization of the rab8-specific membrane traffic route linked to protrusion formation. J. Cell Sci. 119(Pt 23), 4866-4877 (2006).
46. Junutula JR, De Maziere AM, Peden AA et al.: Rab14 is involved in membrane trafficking between the Golgi complex and endosomes. Mol. Biol. Cell 15(5), 2218-2229 (2004).
47. Lombardi D, Soldati T, Riederer MA, Goda Y, Zerial M, Pfeffer SR: Rab9 functions in transport between late endosomes and the trans Golgi network. EMBO J. 12(2), 677-682 (1993).
48. Seaman MN: Endosome protein sorting: Motifs and machinery. Cell Mol. Life Sci. 65(18), 2842-2858 (2008).
49. Barbero P, Bittova L, Pfeffer SR: Visualization of Rab9-mediated vesicle transport from endosomes to the trans-Golgi in living cells. J. Cell Biol. 156(3), 511-518 (2002).
50. Bonifacino JS, Rojas R: Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7(8), 568-579 (2006).
51. Hoekstra D, Tyteca D, van ISC: The subapical compartment: A traffic center in membrane polarity development. J. Cell Sci. 117(Pt 11), 2183-2192 (2004).
52. Hsu VW, Prekeris R: Transport at the recycling endosome. Curr. Opin. Cell Biol. 22(4), 528-534 (2010). n Reviews the family of Rab proteins and discusses how they function to regulate membrane and intracellular trafficking and recycling of material.
53. Jing J, Prekeris R: Polarized endocytic transport: The roles of rab11 and rab11-fips in regulating cell polarity. Histol. Histopathol. 24(9), 1171-1180 (2009).
54. Jones MC, Caswell PT, Norman JC: Endocytic recycling pathways: Emerging regulators of cell migration. Curr. Opin. Cell Biol. 18(5), 549-557 (2006).
55. Maxfield FR, McGraw TE: Endocytic recycling. Nat. Rev. Mol. Cell Biol. 5(2), 121-132 (2004).
56. Sonnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M: Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J. Cell Biol. 149(4), 901-914 (2000).
57. Zerial M, McBride H: Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2(2), 107-117 (2001).
58. Cayouette S, Bousquet SM, Francoeur N et al.: Involvement of Rab9 and Rab11 in the intracellular trafficking of TRPC6. Biochim. Biophys. Acta 1803(7), 805-812 (2010).
59. Sheff DR, Daro EA, Hull M, Mellman I: The receptor recycling pathway contains two distinct populations of early endosomes with different sorting functions. J. Cell Biol. 145(1), 123-139 (1999).
60. Ullrich O, Reinsch S, Urbe S, Zerial M, Parton RG: Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol. 135(4), 913-924 (1996).
61. van der Sluijs P, Hull M, Huber LA, Male P, Goud B, Mellman I: Reversible phosphorylation - dephosphorylation determines the localization of Rab4 during the cell cycle. EMBO J. 11(12), 4379-4389 (1992).
62. Chen W, Wandinger-Ness A: Expression and functional analyses of Rab8 and Rab11a in exocytic transport from trans-Golgi network. Methods Enzymol. 329, 165-175 (2001).
63. Larance M, Ramm G, Stockli J et al.: Characterization of the role of the Rab GTPase-activating protein as160 in insulin-regulated GLUT4 trafficking. J. Biol. Chem. 280(45), 37803-37813 (2005).
64. Cox D, Lee DJ, Dale BM, Calafat J, Greenberg S: A Rab11-containing rapidly recycling compartment in macrophages that promotes phagocytosis. Proc. Natl Acad. Sci. USA 97(2), 680-685 (2000).
65. Jordens I, Marsman M, Kuijl C, Neefjes J: Rab proteins, connecting transport and vesicle fusion. Traffic 6(12), 1070-1077 (2005).
66. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B: HIV-1 TAT enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol. Biol. Cell 15(5), 2347-2360 (2004).
67. Murray JL, Mavrakis M, McDonald NJ et al.: Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J. Virol. 79(18), 11742-11751 (2005).
68. Varthakavi V, Smith RM, Martin KL et al.: The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7(3), 298-307 (2006). Demonstrated that Vpu-mediated HIV particle release occurs via recycling endosomes. This suggests that vital parts of the HIV lifecycle occurs within recycling compartments.
69. Jovic M, Sharma M, Rahajeng J, Caplan S: The early endosome: A busy sorting station for proteins at the crossroads. Histol. Histopathol. 25(1), 99-112 (2010).
70. Yamamoto H, Koga H, Katoh Y, Takahashi S, Nakayama K, Shin HW: Functional cross-talk between Rab14 and Rab4 through a dual effector, RUFY1/Rabip4. Mol. Biol. Cell 21(15), 2746-2755 (2010).
71. Luzio JP, Parkinson MD, Gray SR, Bright NA: The delivery of endocytosed cargo to lysosomes. Biochem. Soc. Trans. 37(Pt 5), 1019-1021 (2009).
72. Blott EJ, Griffiths GM: Secretory lysosomes. Nat. Rev. Mol. Cell Biol. 3(2), 122-131 (2002).
73. Parent A, Hamelin E, Germain P, Parent JL: Rab11 regulates the recycling of the b2-adrenergic receptor through a direct interaction. Biochem. J. 418(1), 163-172 (2009).
74. Pasqualato S, Senic-Matuglia F, Renault L, Goud B, Salamero J, Cherfils J: The structural GDP/GTP cycle of Rab11 reveals a novel interface involved in the dynamics of recycling endosomes. J. Biol. Chem. 279(12), 11480-11488 (2004).
75. Schonteich E, Wilson GM, Burden J et al.: The Rip11/Rab11-FIP5 and kinesin II complex regulates endocytic protein recycling. J. Cell Sci. 121(Pt 22), 3824-3833 (2008).